Biotech / Medical
Axsome Therapeutics (AXSM)
An SI Board Since March 2017
Posts SubjectMarks Bans Symbol
26 1 0 axsm
Emcee:  BioHero Type:  Moderated
Undiscovered and massive undervalued Biotech Stock with many Big News on the way . Axsome has 5 Phase 3 in various indication targeting very large Markets including Alzheimer and Depression .This Stock is brutally undervalued with Market cap of $83 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) over 50% of O/S is owned by Insider and Institutions which is a good sign .

This undiscovered Stock could be the next 10 bagger if only one of their 5 Phase 3 program is successful .GL

Axsome (AXSM)

Market-Cap: $83 Million
Cash: $50.6 Million (cash runway into the first quarter of 2019)

Shares Out: 23 Million

Anticipated Near-Term Clinical Milestones

AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions in Phase 3 (SPA & Fast Track
) ---7M patients in the U.S.

AXS-02 CREATE-1 Complex regional pain syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) ---No approved drug = high unmet need. 80,000 new cases per year in the U.S.

AXS-02 Chronic Low Back Pain Associated with Modic Changes in Phase 3 ---1.6M patients in the U.S.

AXS-05 Agitation in patients with Alzheimer’s disease(AD) in Phase 2/3 ---
No approved medication = unmet medical need. 2M patients in the U.S.

AXS-05 STRIDE-1 Treatment resistant depression in Phase 3 ---Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.

New Presentation March 31

Major Shareholders

Herriott Tabuteau, MD 7 351 729 38,4%
Fidelity Management & Research Co. 2 361 625 12,3%
JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48%
Mark Coleman, MD 647 998 3,38%
BlackRock Fund Advisors 426 837 2,23%
Stifel Trust Co., NA 415 279 2,17%
The Vanguard Group, Inc. 272 189 1,42%
Lombard Odier Asset Management (USA) Corp. 250 000 1,31%
JPMorgan Investment Management, Inc. 156 625 0,82%
SSgA Funds Management, Inc. 134 688 0,70%

Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
26AXSM = Market Cap $70 Million / Cash $41 Million or untill Q4 2019 / Shares OutBioHero-January 17
25AXSM could be the next 4 - 6 bagger biotechstock
24 Looks like the runup to phase 3 results has just begun...GL "JPMorgan BioHero-12/28/2017
23 Looks like breakout is on the way ..2x Phase 3 readout expected within dayBioHero-12/26/2017
22Biotech Penny Stocks to Buy for January, No. 4: Axsome Therapeutics Inc....DecemBioHero-12/22/2017
212 BIG P3 READOUT THIS MONTH=$$$$$ GET SOME AXSM AXSM (MC $120 M) (Cash $40 BioHero-12/20/2017
20MACD and RSI(14) show bullish signs. [graphic]hollyhunter-7/30/2017
19Ladenburg Thalmann raised its price target on Axsome Therapeutics (NASDAQ: AXSM)BioHero-7/26/2017
18Nice price jump looks like its on the way to break the size back the MA(200) at BioHero-6/20/2017
17 Fantastic new director appointed ,, she really must like what she sees at AxsoBioHero-6/19/2017
16Nice move today ,, Start Phase 2/3 of Alzheimer agitation trial within days.....BioHero-6/6/2017
15Almost 1.9 Million shares bought by new institutional investors alone in this moBioHero-5/25/2017
14Another nice move today, next near term tgt is to size back the MA(200) at arounBioHero-5/22/2017
13and another buy rating out today with tgt $14 Axsome Therapeutics BioHero-5/19/2017
12Another Guy likes AXSM ...more and more people discover this stock and realize tBioHero-5/16/2017
11Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome ThBioHero-5/12/2017
10Well written article out by J.Napodano Should You Invest In Axsome TherapeuticBioHero-5/9/2017
9Fantastic News out today... Axsome Therapeutics Receives FDA Fast Track DesignaBioHero-5/8/2017
8New Investor bought a MASSIVE stake of 1.3 Million shares 5.5% , now the majoritBioHero-4/28/2017
7Bullish crossover in MACD and Stochastic oscillator. [graphic]hollyhunter-4/13/2017
6Up she goes ,i think this dirt cheap stock will be over $5 within days BioHero-4/11/2017
5Very nice accumulation ongoing in last days ,this one will be over $10 before yBioHero-4/7/2017
4MarketCap $95M /Cash $50M /5x Phase 3 = Definitely one of the most undervalued BBioHero-3/30/2017
3Hey guys if you own shares of this low float stock then please put a high GTC sBioHero-3/28/2017
2maybe the cheapest Nasdaq Biotech you can get with 5x Phase 3 in various indicaBioHero-3/27/2017
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.